India’s drug regulator has clarified that new drugs not approved anywhere globally must undergo the full domestic regulatory process, even if Indian patients participated in global clinical trials. CDSCO said such applications require comprehensive safety and efficacy evaluation under existing rules.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.